AN2 Therapeutics receives FDA IND clearance for epetraborole in polycythemia vera, completing approvals in Australia, India ...

Pfizer Q3 2026 earnings: second positive Elrexfio Phase III readout, atirmociclib tolerability data and mevrometostat delay.

Servier's sevasemten missed its Phase III GRAND CANYON primary endpoint in Becker muscular dystrophy. Read how these results ...

Camurus has dosed the first patient in LUNAR-2, a Phase IIb study of monthly semaglutide depot CAM2056 for obesity. Explore ...

Ensem registers a Phase I/II trial of oral pan-KRAS inhibitor ETX-929 for KRAS-altered solid tumors. Learn how it's tested ...

Columbia researchers show deleting certain sugar transport genes helps E. coli colonize tumors better. Learn how this could ...

Thryv Therapeutics secures $30M Series B to launch the ASPIRE-HF heart failure study of its SGK1 inhibitor. Read how this ...

Beijing Mabworks' MBS314 trispecific antibody (GPRC5D, BCMA, CD3) cleared by China's NMPA for first-in-human myeloma trial.

Lytix Biopharma's Phase II NeoLIPA trial of ruxotemitide plus pembrolizumab met its melanoma endpoint. Read what the results ...

Specific Biologics closes a $35M Series A to advance its Dualase gene-editing therapy into a Phase I/II trial for ...

Phase closes a $30M Series D led by Viking Global Investors to scale its nPhase.ai clinical data platform. Read on to see how ...

Fresenius partners with WuXi Biologics in an exclusive deal to develop and manufacture up to 37 biosimilar candidates, its ...